Advertisement
Organisation › Details
Janssen Pharmaceutica N.V. (BE)
Within the Johnson & Johnson group, Janssen Pharmaceutica is a worldwide Center of Excellence for integrated R&D, production and general services. In Belgium, the company has sites in Beerse, Geel and Olen, which together account for a workforce of 4,350 persons. With more than 80 drugs to its credit, the company is one of the most innovative in the world and its products are used worldwide in human and animal medicine, and plant and material protection. *
Start | 1961-01-01 acquired | |
Group | Johnson & Johnson (JnJ) (Group) | |
Industry | pharmaceutical | |
Region | Beerse | |
Country | Belgium | |
City | n. a. | |
Address record changed: 2011-05-15 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Johnson & Johnson (JnJ) (Group)
- [1] Addex Therapeutics S.A.. (7/22/24). "Press Release: Addex’s Partner Discontinues ADX71149 Development in Epilepsy". Geneva....
- [2] Bright Peak Therapeutics AG. (6/11/24). "Press Release: Bright Peak Therapeutics Announces $90 Million in Series C Financing to Advance First-in-Class PD1-IL18 Immunoconjugate Program Into Clinical Trials". Basel & San Diego, CA....
- [3] Numab Therapeutics AG. (5/28/24). "Press Release: Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis". H...
- [4] Addex Therapeutics S.A.. (4/29/24). "Press Release: Addex Provides Update on ADX71149 Phase 2 Epilepsy Study". Geneva....
- [5] Basel Area Business & Innovation. (4/26/24). "Press Release: Johnson & Johnson Opens Innovation Hub in Allschwil"....
- [6] Recursion Pharmaceuticals, Inc.. (4/16/24). "Press Release: Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer". Salt Lake City, UT....
- [7] Asgard Therapeutics AB. (3/14/24). "Press Release: Asgard Therapeutics Announces €30 Million Series A Financing to Advance Its First-in-Class in vivo Cell Reprogramming Platform for Immuno-oncology". Lund....
- [8] Johnson & Johnson. (1/8/24). "Press Release: Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer". New Brunswick, NJ....
- [9] LegoChem Biosciences, Inc.. (12/26/23). "Press Release: LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC". Daejeon....
- [10] Sanofi S.A.. (10/3/23). "Press Release: Sanofi Announces Agreement for Potential First-in-Class Vaccine against Extraintestinal Pathogenic E. coli". Paris....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top